Zimmer Biomet (NYSE: ZBH) officially inaugurated its new $120 million advanced manufacturing facility in Alajuela, Costa Rica, on October 12, 2026. The 150,000-square-foot plant is dedicated exclusively to the production of the company's trauma and extremities portfolio. As global orthopedic supply chains continue to struggle with extended lead times and contract manufacturing bottlenecks, this strategic "nearshoring" investment aims to stabilize the output of critical fracture fixation hardware for the Americas and global distribution networks.
Addressing the Trauma Supply Chain Bottleneck
Over the past two years, the orthopedic trauma sector has faced chronic backorders, driven by consolidation among tier-one contract manufacturers and intermittent raw material shortages. Unlike elective joint reconstruction, trauma surgery is non-deferrable; acute fractures cannot be scheduled around implant factory lead times.
The new Costa Rica hub is engineered to mitigate these vulnerabilities by vertically integrating production. The facility incorporates automated CNC multiaxis machining, direct metal laser sintering (DMLS) for complex geometries, and in-house sterile packaging lines. According to the company's regional leadership, the site is projected to increase Zimmer Biomet's overall global trauma manufacturing capacity by 25% once it reaches full operational scale in mid-2027.
Focus on Extremities and High-Demand Hardware
To maximize immediate supply chain relief, the facility will prioritize the manufacturing of high-volume, standard-of-care implant systems. Initial production lines are focusing heavily on the A.L.P.S.® (Anatomic Locked Plating System) family, producing anatomically pre-contoured plates targeting wrist and hand fractures as well as comprehensive lower extremity trauma sets. By expanding its internal manufacturing footprint, Zimmer Biomet reduces its reliance on third-party vendors, shortening the transit time from factory floor to central distribution hubs.
The BoneCraft Angle
For regional medical device distributors and hospital procurement teams, major capacity expansions by top-tier OEMs are positive long-term indicators. However, ramping up a new manufacturing facility requires complex regulatory validations, meaning it will take several quarters for this new capacity to alleviate current market backorders.
BoneCraft bridges this critical gap. As an independent distributor of genuine orthopedic trauma implants, we do not rely on future production runs to supply our clients. We maintain deep, factory-sealed wholesale warehouse inventory. We shield our hospital and distributor partners from OEM allocation limits and factory delays, ensuring that critical tibia and fibula plating systems, intramedullary nails, and standard bone screws remain available for immediate 24-hour dispatch.
Sources
- Zimmer Biomet Investor Relations — Zimmer Biomet Inaugurates Advanced Manufacturing Facility in Costa Rica, October 12, 2026
- MassDevice — Zimmer Biomet Expands Trauma Production Footprint with $120M Costa Rica Site
- Orthopedic Design & Technology (ODT) — Nearshoring Trends in Orthopedic Manufacturing: 2026 Supply Chain Outlook
A.L.P.S. is a registered trademark of Zimmer Biomet. BoneCraft is an independent distributor of genuine orthopedic trauma implants and is not affiliated with, sponsored by, or endorsed by Zimmer Biomet.
-
BoneCraft Medical & Technical Editorial Team
Orthopedic Fixation Specialists
The BoneCraft Editorial Team comprises biomedical specialists and medical device supply chain experts. Dedicated to surgical transparency and technical precision, we publish insights on trauma plating, intramedullary fixation, and biomechanical implant performance. Our content synthesizes established surgical techniques, clinical literature, and exact specifications for genuine Zimmer Biomet orthopedic products to support global healthcare distributors and procurement teams.
